In fiscal 2025, which ended Dec 31, 2025, Sangamo Therapeutics, Inc. reported revenue of $39.6 million, down 31.6% from the year before. It recorded a net loss of $122.9 million. The operating loss came to $121.2 million, an operating margin of -306.5%. Diluted earnings per share were -$0.44. Over the twelve months ended Mar 31, 2026, revenue was $34.6 million and the net loss was $123.3 million. Across the 10 fiscal years shown, revenue grew from $19.4 million in fiscal 2016 to $39.6 million in fiscal 2025, about 8.2% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Mar 31, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
35
-45.8%
|
40
-31.6%
|
58
-67.2%
|
176
+58.3%
|
111
+0.5%
|
111
-6.3%
|
118
+15.4%
|
102
+21.3%
|
84
+131.0%
|
37
+88.6%
|
19
-51.0%
|
| Research and development |
113
+11.4%
|
113
+1.0%
|
112
-52.4%
|
234
-6.3%
|
250
+8.3%
|
231
+27.8%
|
181
+23.8%
|
146
+27.0%
|
115
+74.8%
|
66
+0.2%
|
66
-2.4%
|
| Selling, general and administrative |
32
-26.4%
|
35
-22.0%
|
45
-26.9%
|
61
-2.4%
|
63
-0.8%
|
63
-5.8%
|
67
+8.8%
|
62
+32.0%
|
47
+71.8%
|
27
+3.3%
|
26
+37.2%
|
| Restructuring and impairment |
—
|
-1
-261.4%
|
0
-97.9%
|
16
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Operating income |
-124
-50.5%
|
-121
-16.6%
|
-104
+62.1%
|
-274
-36.1%
|
-201
-9.8%
|
-183
-41.5%
|
-130
-23.2%
|
-105
-36.3%
|
-77
-36.9%
|
-56
+22.3%
|
-73
-54.9%
|
| Interest income |
—
|
1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Foreign currency gain (loss) |
-2
|
-4
|
—
|
—
|
—
|
—
|
—
|
—
|
-1
|
—
|
—
|
| Pretax income |
-124
-55.8%
|
-124
-25.9%
|
-98
+62.7%
|
-263
-37.0%
|
-192
-7.8%
|
-178
-47.4%
|
-121
-26.6%
|
-95
-38.5%
|
-69
-26.2%
|
-55
+23.9%
|
-72
-54.4%
|
| Income tax |
-1
-370.5%
|
-1
-240.1%
|
-0
+96.7%
|
-5
-1282.3%
|
0
+40.2%
|
0
-11.3%
|
0
|
0
+100.0%
|
—
|
—
|
-0
+99.8%
|
| Net income |
-123
-55.2%
|
-123
-25.5%
|
-98
+62.0%
|
-258
-34.1%
|
-192
-7.8%
|
-178
-47.3%
|
-121
-27.1%
|
-95
-39.3%
|
-68
-25.2%
|
-55
+23.8%
|
-72
-76.1%
|
| Basic EPS |
-0.38
-2.1%
|
-0.44
+10.2%
|
-0.49
+66.9%
|
-1.48
-18.4%
|
-1.25
-1.6%
|
-1.23
|
—
|
—
|
—
|
—
|
—
|
| Diluted EPS |
-0.38
-2.1%
|
-0.44
+10.2%
|
-0.49
+66.9%
|
-1.48
-18.4%
|
-1.25
-1.6%
|
-1.23
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, basic |
322
+52.0%
|
280
+38.9%
|
202
+15.6%
|
174
+13.0%
|
154
+6.8%
|
145
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, diluted |
322
+52.0%
|
280
+38.9%
|
202
+15.6%
|
174
+13.0%
|
154
+6.8%
|
145
|
—
|
—
|
—
|
—
|
—
|
| Other measures | |||||||||||
| Depreciation and amortization |
4
-22.5%
|
4
-22.4%
|
5
-66.1%
|
15
+24.4%
|
12
+28.3%
|
9
+66.1%
|
6
+44.6%
|
4
+66.6%
|
2
+57.5%
|
1
+50.3%
|
1
+0.9%
|
| EBITDA |
-120
-55.0%
|
-117
-18.6%
|
-99
+61.8%
|
-259
-36.9%
|
-189
-8.8%
|
-174
-40.4%
|
-124
-22.3%
|
-101
-35.4%
|
-75
-36.3%
|
-55
+23.3%
|
-72
-56.0%
|
| Margins | |||||||||||
| Operating margin |
-357.55%
|
-306.53%
|
-179.88%
|
-155.48%
|
-180.85%
|
-165.61%
|
-109.61%
|
-102.69%
|
-91.35%
|
-154.13%
|
-374.23%
|
| Pretax margin |
-358.88%
|
-312.25%
|
-169.74%
|
-149.18%
|
-172.37%
|
-160.79%
|
-102.19%
|
-93.16%
|
-81.57%
|
-149.23%
|
-369.65%
|
| Profit margin |
-356.89%
|
-310.81%
|
-169.45%
|
-146.30%
|
-172.76%
|
-161.05%
|
-102.37%
|
-92.93%
|
-80.91%
|
-149.23%
|
-369.58%
|
| EBITDA margin |
-346.95%
|
-296.52%
|
-171.04%
|
-146.93%
|
-169.97%
|
-157.09%
|
-104.80%
|
-98.85%
|
-88.56%
|
-150.03%
|
-369.09%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SGMOQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Richmond, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1001233
- Former names
- SANGAMO BIOSCIENCES INC (until Jan 6, 2017)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.